Psychedelics, such as psilocybin and lysergic acid diethylamide, ­ modulate neuroplasticity and brain connectivity via 5-HT2A recep- tors. Their efficacy has been demonstrated in depression and ­ anxiety, where they are particularly interesting because of their ­ rapid and long-lasting effect. They could also be beneficial for ­ addictions, post-traumatic stress, and obsessive-compulsive disorder. This article ­ explores their therapeutic potential in Parkinson’s ­ disease (PD), both symptomatically in PD depression, anxiety, and impulse control ­ disorders, and in terms of neuroprotection. Psy- chedelics actually ­ stimulate synaptogenesis, increase brain-derived neurotrophic factor, and exert anti-inflammatory effects. Although promising, these treatments require clinical trials to confirm their safety and efficacy in PD.